Up next


Today in Biotech Ep 002: Abeona Closing of $25 Million, ADHD treatment, Novartis, & ... July 7, 2023

7 Views
Redbrick Bio
0
Published on 08 Jul 2023 / In Entertainment

July 7, 2023 "Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules" "Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults"" "Researchers find weaker immune response to viral infections in children with mitochondrial disorders" "Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook" #celltherapy #genetherapy #adhd #medicine #precisionmedicine #redbrickbio #Abeona #novartis #nih #Axsome

Show more
0 Comments sort Sort By

Up next